• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [16733 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     NIHR Health Technology Assessment programme Shockwave lithotripsy compared with ureteroscopic stone treatment for adults with ureteric stones: the TISU non-inferiority RCT
2022     Agency for Healthcare Research and Quality (AHRQ) Telehealth for women's preventive services
2022     Agency for Care Effectiveness (ACE) Infliximab biosimilar for treating inflammatory conditions
2022     Swiss Federal Office of Public Health (FOPH) Medicines for dementia due to Alzheimer's disease and Parkinson's disease
2022     Agency for Care Effectiveness (ACE) Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis
2022     National Institute for Health and Care Excellence (NICE) PLGF-based testing to help diagnose suspected preterm pre-eclampsia. NICE diagnostics guidance 49
2022     NIHR Health Technology Assessment programme Development, implementation and evaluation of an early warning system improvement programme for children in hospital: the PUMA mixed-methods study
2022     Swiss Federal Office of Public Health (FOPH) Thyroid function tests for the diagnosis of suspected primary or secondary thyroid dysfunction
2022     NIHR Health Technology Assessment programme Synthetic sling or artificial urinary sphincter for men with urodynamic stress incontinence after prostate surgery: the MASTER non-inferiority RCT
2022     NIHR Public Health Research (PHR) programme A group-based exercise and behavioural maintenance intervention for adults over 65 years with mobility limitations: the REACT RCT
2022     Agency for Healthcare Research and Quality (AHRQ) Transitions of care from pediatric to adult services for children with special healthcare needs
2022     National Institute for Health and Care Excellence (NICE) PredictSURE IBD and IBDX to guide treatment of Crohn's disease. NICE diagnostics guidance 45
2022     National Institute for Health and Care Excellence (NICE) EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules. NICE diagnostics guidance 46
2022     Agency for Care Effectiveness (ACE) Disease-modifying therapies for treating multiple sclerosis
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for acute lymphoblastic leukaemia
2022     Agency for Care Effectiveness (ACE) Long-acting erythropoiesis-stimulating agents for treating anaemia in chronic kidney disease
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors, immune checkpoint inhibitors and everolimus for treating advanced renal cell cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced gastric cancer
2022     Agency for Care Effectiveness (ACE) Update of MOH list of subsidised drugs to include treatments for various cancer conditions
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors for treating ALK mutation-positive advanced non-small-cell lung cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for prostate cancer
2022     Agency for Care Effectiveness (ACE) Cetuximab and panitumumab for treating RAS wild-type colorectal cancer
2022     Agency for Care Effectiveness (ACE) Regorafenib and sunitinib for treating advanced gastrointestinal stromal tumours
2022     NIHR Health Technology Assessment programme A multidomain decision support tool to prevent falls in older people: the FinCH cluster RCT
2022     Agency for Care Effectiveness (ACE) Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer
2022     Agency for Care Effectiveness (ACE) Eltrombopag for treating immune thrombocytopenia and severe aplastic anaemia
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating differentiated thyroid cancer
2022     National Institute for Health and Care Excellence (NICE) Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis. NICE interventional procedures guidance 746
2022     Agency for Care Effectiveness (ACE) Immune checkpoint inhibitors and BRAK/MEK inhibitors for treating advanced malignant melanoma
2022     National Institute for Health and Care Excellence (NICE) Ab interno canaloplasty for open-angle glaucoma. NICE interventional procedures guidance 745
2022     NIHR Health Technology Assessment programme Supraglottic airway device versus tracheal intubation in the initial airway management of out-of-hospital cardiac arrest: the AIRWAYS-2 cluster RCT
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated multiple myeloma
2022     National Institute for Health and Care Excellence (NICE) Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules. NICE interventional procedures guidance 743
2022     Agency for Care Effectiveness (ACE) Everolimus, lanreotide, octreotide and sunitinib for treating advanced neuroendocrine tumours
2022     National Institute for Health and Care Excellence (NICE) Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder. NICE interventional procedures guidance 742
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma
2022     National Institute for Health and Care Excellence (NICE) Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine. NICE interventional procedures guidance 740
2022     Agency for Care Effectiveness (ACE) Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
2022     National Institute for Health and Care Excellence (NICE) YAG laser vitreolysis for symptomatic vitreous floaters. NICE interventional procedures guidance 741
2022     Agency for Care Effectiveness (ACE) Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer
2022     National Institute for Health and Care Excellence (NICE) Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain. NICE interventional procedures guidance 739
2022     Agency for Care Effectiveness (ACE) Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine
2022     National Institute for Health and Care Excellence (NICE) Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 737
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced hepatocellular carcinoma
2022     National Institute for Health and Care Excellence (NICE) Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause. NICE interventional procedures guidance 738
2022     Agency for Care Effectiveness (ACE) High-strength insulin glargine for treating type 1 and 2 diabetes mellitus
2022     National Institute for Health and Care Excellence (NICE) Focal resurfacing implants to treat articular cartilage damage in the knee. NICE interventional procedures guidance 734
2022     Agency for Care Effectiveness (ACE) Bevacizumab for treating persistent, recurrent or metastatic cervical cancer
2022     National Institute for Health and Care Excellence (NICE) Transcutaneous electrical neuromuscular stimulation for urinary incontinence. NICE interventional procedures guidance 735
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Systematic review of health care interventions in the context of return to work for persons being at risk for long-term sick leave]
2022     Agency for Care Effectiveness (ACE) Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer
2022     National Institute for Health and Care Excellence (NICE) Superficial venous arterialisation for chronic limb threatening ischaemia. NICE interventional procedures guidance 736
2022     Agency for Care Effectiveness (ACE) Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension
2022     National Institute for Health and Care Excellence (NICE) Bioresorbable stent implantation to treat coronary artery disease. NICE interventional procedures guidance 732
2022     NIHR Health Technology Assessment programme Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT
2022     Agency for Care Effectiveness (ACE) PARP inhibitors and bevacizumab for treating advanced ovarian cancer
2022     National Institute for Health and Care Excellence (NICE) Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection. NICE interventional procedures guidance 733
2022     Agency for Care Effectiveness (ACE) Bevacizumab biosimilar for treating different types of cancers
2022     National Institute for Health and Care Excellence (NICE) Transcatheter tricuspid valve annuloplasty for tricuspid regurgitation. NICE interventional procedures guidance 730
2022     Penn Medicine Center for Evidence-based Practice (CEP) Restrictive red blood cell (RBC) transfusion thresholds: update
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2022     National Institute for Health and Care Excellence (NICE) Transcatheter tricuspid valve leaflet repair for tricuspid regurgitation. NICE interventional procedures guidance 731
2022     NIHR Health Technology Assessment programme Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling
2022     Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2022     National Institute for Health and Care Excellence (NICE) Vertebral body tethering for idiopathic scoliosis in children and young people. NICE interventional procedures guidance 728
2022     Swiss Federal Office of Public Health (FOPH) Denosumab (Prolia®) for the treatment of osteoporosis
2022     NIHR Public Health Research (PHR) programme E-health interventions targeting STIs, sexual risk, substance use and mental health among men who have sex with men: four systematic reviews
2022     Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2022     National Institute for Health and Care Excellence (NICE) Nerve graft for corneal denervation. NICE interventional procedures guidance 729
2022     Swiss Federal Office of Public Health (FOPH) Trimonthly vs. monthly use of bone-targeted agents in patients with bone metastases and multiple myeloma
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Folate testing. [Protocol]
2022     National Institute for Health and Care Excellence (NICE) Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus). NICE interventional procedures guidance 727
2022     Swiss Federal Office of Public Health (FOPH) Sedative-hypnotic drugs for the treatment of primary chronic insomnia disorder
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Revascularisation versus optimal medical therapy (OMT) for the treatment of chronic coronary syndrome (CCS). [Protocol]
2022     National Institute for Health and Care Excellence (NICE) Endoanchoring systems in endovascular aortic aneurysm repair. NICE interventional procedures guidance 725
2022     Swiss Federal Office of Public Health (FOPH) Levothyroxine for patients diagnosed with subclinical hypothyroidism
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Denosumab (Prolia) for the treatment of osteoporosis
2022     National Institute for Health and Care Excellence (NICE) Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis. NICE interventional procedures guidance 726
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Calcitonin gene-related peptide antagonists for the prevention of migraine [Protocol]
2022     National Institute for Health and Care Excellence (NICE) Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome. NICE interventional procedures guidance 724
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Oral anticoagulants for prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation. [Protocol]
2022     National Institute for Health and Care Excellence (NICE) Liposuction for chronic lymphoedema. NICE interventional procedures guidance 723
2022     National Institute for Health and Care Excellence (NICE) Intramedullary distraction for upper limb lengthening. NICE interventional procedures guidance 722
2022     National Institute for Health and Care Excellence (NICE) Liposuction for chronic lipoedema. NICE interventional procedures guidance 721
2022     NIHR Health Technology Assessment programme Endovascular stent grafting and open surgical replacement for chronic thoracic aortic aneurysms: a systematic review and prospective cohort study
2022     NIHR Health Technology Assessment programme Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis
2022     National Institute for Health and Care Excellence (NICE) Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis. NICE interventional procedures guidance 720
2022     Health Technology Wales (HTW) Virtual reality interventions for the management of pain associated with medical procedures
2022     National Institute for Health and Care Excellence (NICE) Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach. NICE interventional procedures guidance 717
2022     NIHR Health Technology Assessment programme A large randomised assessment of the relative cost-effectiveness of different classes of drugs for Parkinson's disease (PD MED)
2022     National Institute for Health and Care Excellence (NICE) Intramedullary distraction for lower limb lengthening. NICE interventional procedures guidance 718
2022     Agency for Care Effectiveness (ACE) Negative pressure wound therapy for wound management in patients with diabetes (type 1 and 2)
2022     National Institute for Health and Care Excellence (NICE) Endoscopic balloon dilation for subglottic or tracheal stenosis. NICE interventional procedures guidance 719
2022     NIHR Health Technology Assessment programme Telaprevir for the treatment of genotype 1 chronic hepatitis C
2022     NIHR Health Technology Assessment programme Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial
2022     Agency for Care Effectiveness (ACE) Brentuximab vedotin for treating T-cell lymphoma
2022     National Institute for Health and Care Excellence (NICE) Stereotactic radiosurgery for trigeminal neuralgia. NICE interventional procedures guidance 715
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating advanced urothelial carcinoma
2022     National Institute for Health and Care Excellence (NICE) Microwave ablation for primary or metastatic cancer in the lung. NICE interventional procedures guidance 716
2022     Agency for Care Effectiveness (ACE) Ruxolitinib for treating polycythaemia vera